Cutaneous Squamous Cell Carcinoma Cscc clinical trials

Explore recruiting cutaneous squamous cell carcinoma cscc clinical trials.

Recruiting cutaneous squamous cell carcinoma cscc studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cutaneous Squamous Cell Carcinoma Cscc trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Mechanisms of Resistance to anti-PD-1 Therapy in cutaneous Squamous Cell Carcinomas: Impact of Tumor Cell Plasticity on Promoting Myeloid Suppressor Cell Infiltration. A phase II single arm, unicenter study of cemiplimab in patients with locally advanced cSCCs.

Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Controlled, Open-Label, Phase 2 Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma [CERPASS]

Spain, Greece, Germany, Poland, Bulgaria, France

Therapeutic exploratory (Phase II) EU CTIS Study details

A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF ADJUVANT CEMIPLIMAB VERSUS PLACEBO AFTER SURGERY AND RADIATION THERAPY IN PATIENTS WITH HIGH RISK CUTANEOUS SQUAMOUS CELL CARCINOMA

Ireland, Poland, France, Germany, Greece, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2 Study of Neoadjuvant Cemiplimab for Stage II to IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Open-label, Phase 2 study of Intratumoral Vidutolimod (CMP-001) in Combination with Intravenous Cemiplimab in Subjects with Selected Types of Advanced or Metastatic Cancer

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions.

Poland, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Cutaneous Squamous Cell Carcinoma Cscc trials by city

Cutaneous Squamous Cell Carcinoma Cscc in Toronto Cutaneous Squamous Cell Carcinoma Cscc in Vancouver Cutaneous Squamous Cell Carcinoma Cscc in Montreal Cutaneous Squamous Cell Carcinoma Cscc in Calgary Cutaneous Squamous Cell Carcinoma Cscc in Edmonton Cutaneous Squamous Cell Carcinoma Cscc in Ottawa Cutaneous Squamous Cell Carcinoma Cscc in Winnipeg Cutaneous Squamous Cell Carcinoma Cscc in Quebec City Cutaneous Squamous Cell Carcinoma Cscc in Hamilton Cutaneous Squamous Cell Carcinoma Cscc in Kitchener Cutaneous Squamous Cell Carcinoma Cscc in London Cutaneous Squamous Cell Carcinoma Cscc in Halifax Cutaneous Squamous Cell Carcinoma Cscc in New York Cutaneous Squamous Cell Carcinoma Cscc in Los Angeles Cutaneous Squamous Cell Carcinoma Cscc in Chicago Cutaneous Squamous Cell Carcinoma Cscc in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease